SETD2 mutations are observed in ~10% of human ccRCC primary tumors, and the frequency dramatically increase to ~30% in metastatic ccRCC patient samples, thereby suggesting a role for this genetic alteration in driving the metastatic progression of ccRCC2,3,7,9. This evidence concerns the gene SETD2 and nonpapillary renal cell carcinoma.